Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G M Higa

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
American Journal of Hospital Pharmacy|February 1, 1994
Tamoxifen: 25-year perspectiveG M Higa
Pharmacotherapy|March 24, 2000
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitorsG M Higa
Pharmacotherapy|December 17, 1998
Acute effects of prechemotherapy filgrastim administration on late hematopoietic progenitor cellsG M Higa
The New England Journal of Medicine|January 23, 1992
G-CSF for fever and neutropenia induced by chemotherapyG M Higa
The West Virginia Medical Journal|July 1, 1995
Scientific publications and scientific styleG M Higa
The Annals of Pharmacotherapy|January 1, 1994
Significance of granulocyte colony-stimulating factor (G-CSF)-induced increases in LDHG M Higa
Expert Opinion on Pharmacotherapy|October 5, 2001
Aromatase inhibitors for breast cancer: pharmacoeconomic considerationsG M Higa
Pharmacoeconomics|August 18, 2000
New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefitsG M Higa
American Journal of Hospital Pharmacy|December 1, 1993
Difficulties in assessing appropriate ondansetron useG M Higa
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 2, 1998
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancerG M Higa, N alKhouri
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
American Journal of Hospital Pharmacy|February 1, 1994
Tamoxifen: 25-year perspectiveG M Higa
Pharmacotherapy|March 24, 2000
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitorsG M Higa
Pharmacotherapy|December 17, 1998
Acute effects of prechemotherapy filgrastim administration on late hematopoietic progenitor cellsG M Higa
The New England Journal of Medicine|January 23, 1992
G-CSF for fever and neutropenia induced by chemotherapyG M Higa
The West Virginia Medical Journal|July 1, 1995
Scientific publications and scientific styleG M Higa
The Annals of Pharmacotherapy|January 1, 1994
Significance of granulocyte colony-stimulating factor (G-CSF)-induced increases in LDHG M Higa
Expert Opinion on Pharmacotherapy|October 5, 2001
Aromatase inhibitors for breast cancer: pharmacoeconomic considerationsG M Higa
Pharmacoeconomics|August 18, 2000
New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefitsG M Higa
American Journal of Hospital Pharmacy|December 1, 1993
Difficulties in assessing appropriate ondansetron useG M Higa
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 2, 1998
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancerG M Higa, N alKhouri
Pageof 2